Evidence map›Paper›PMID 25671302›Full record

ArticleOncotarget2015

Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.

Kazuyuki Matsushita, Kouichi Kitamura, Bahityar Rahmutulla, Nobuko Tanaka, Takayuki Ishige, Mamoru Satoh, Tyuji Hoshino, Satoru Miyagi, Takeshi Mori, Sakae Itoga and 13 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Oncotarget · 2017
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 1 country.

Kazuyuki MatsushitaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Kouichi KitamuraDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Bahityar RahmutullaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Nobuko TanakaDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Takayuki IshigeDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Mamoru SatohDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Tyuji HoshinoDepartment of Physical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana, Chiba, Japan.
Satoru MiyagiDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan.
Takeshi MoriDepartment of Pediatrics, Graduate School of Medicine, Kobe University, Kusunoki-cho, Kobe, Japan.
Sakae ItogaDivision of Laboratory Medicine, Chiba University Hospital, Inohana, Chiba, Japan.
Hideaki ShimadaDepartment of Surgery, School of Medicine, Toho University, Omori-nishi, Ota-ku, Tokyo, Japan.
Takeshi TomonagaLaboratory of Proteome Research, National Institute of Biomedical Innovation, Saito-Asagi, Ibaraki, Osaka, Japan.
Minoru KitoOriental Yeast Co., Ltd. Azusawa, Itabashi-ku, Tokyo, Japan.
Yaeko Nakajima-TakagiDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan.
Shuji KuboDepartment of Genetics, Hyogo College of Medicine, Mukogawa-cho, Nishinomiya, Hyogo Prefecture, Japan.
Chiaki NakasekoDepartment of Haematology, Chiba University Hospital, Inohana, Chiba, Japan.
Masahiko HatanoDepartment of Biomedical Science, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Takashi MikiDepartment of Medical Physiology, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Masafumi MatsuoDepartment of Pediatrics, Graduate School of Medicine, Kobe University, Kusunoki-cho, Kobe, Japan.
Masaki FukuyoDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Atsushi IwamaDepartment of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan.
Fumio NomuraDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
Chiba University · JPChiba University Hospital · JPHyogo Medical University · JPKobe Gakuin University · JPKobe University · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPRicoh (Japan) · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FUSE-binding protein (FBP)-interacting repressor (FIR) is a c-myc transcriptional suppressor. A splice variant of FIR that lacks exon 2 in the transcriptional repressor domain (FIRΔexon2) upregulates c-myc transcription by inactivating wild-type FIR. The ratio of FIRΔexon2/FIR mRNA was increased in human colorectal cancer and hepatocellular carcinoma tissues. Because FIRΔexon2 is considered to be a dominant negative regulator of FIR, FIR heterozygous knockout (FIR⁺/⁻) C57BL6 mice were generated. FIR complete knockout (FIR⁻/⁻) was embryonic lethal before E9.5; therefore, it is essential for embryogenesis. This strongly suggests that insufficiency of FIR is crucial for carcinogenesis. FIR⁺/⁻ mice exhibited prominent c-myc mRNA upregulation, particularly in the peripheral blood (PB), without any significant pathogenic phenotype. Furthermore, elevated FIRΔexon2/FIR mRNA expression was detected in human leukemia samples and cell lines. Because the single knockout of TP53 generates thymic lymphoma, FIR⁺/⁻TP53⁻/⁻ generated T-cell type acute lymphocytic/lymphoblastic leukemia (T-ALL) with increased organ or bone marrow invasion with poor prognosis. RNA-sequencing analysis of sorted thymic lymphoma cells revealed that the Notch signaling pathway was activated significantly in FIR⁺/⁻TP53⁻/⁻ compared with that in FIR⁺/⁺TP53⁻/⁻ mice. Notch1 mRNA expression in sorted thymic lymphoma cells was confirmed using qRT-PCR. In addition, flow cytometry revealed that c-myc mRNA was negatively correlated with FIR but positively correlated with Notch1 in sorted T-ALL/thymic lymphoma cells. Moreover, the knockdown of TP53 or c-myc using siRNA decreased Notch1 expression in cancer cells. In addition, an adenovirus vector encoding FIRΔexon2 cDNA increased bleomycin-induced DNA damage. Taken together, these data suggest that the altered expression of FIRΔexon2 increased Notch1 at least partially by activating c-Myc via a TP53-independent pathway. In conclusion, the alternative splicing of FIR, which generates FIRΔexon2, may contribute to both colorectal carcinogenesis and leukemogenesis.

Indexed as

AdultAlternative SplicingAnimalsDisease ProgressionFemaleHaploinsufficiencyHumansMaleMiceMice, Inbred C57BLMice, KnockoutPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-mycReceptor, Notch1Repressor ProteinsRNA-Binding ProteinsNOTCH1 protein, humanNotch1 protein, mousepoly-U binding splicing factor 60KDaProto-Oncogene Proteins c-mycReceptor, Notch1Repressor ProteinsRNA-Binding ProteinsRNA Splicing FactorsTumor Suppressor Protein p53FBP interacting repressor (FIR)haplo-insufficiencyleukemiaP53splicing variantT-ALL

Identifiers

PMID25671302
PMCPMC4467136
OpenAlexW1579411082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.